Halozyme Therapeutics (NASDAQ:HALO) Posts Earnings Results, Beats Expectations By $0.49 EPS

Halozyme Therapeutics (NASDAQ:HALO) announced its quarterly earnings results on Thursday. The biopharmaceutical company reported $2.28 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.79 by $0.49, FiscalAI reports. The company had revenue of $481.00 million during the quarter, compared to the consensus estimate of $402.28 million. Halozyme Therapeutics had a return on equity of 187.91% and a net margin of 23.13%.The company’s revenue for the quarter was up 47.7% compared to the same quarter last year. During the same period in the prior year, the company earned $1.54 earnings per share. Halozyme Therapeutics updated its FY 2026 guidance to 8.650-9.000 EPS.

Here are the key takeaways from Halozyme Therapeutics’ conference call:

• Record second-quarter performance: Total revenue rose 48% year over year to $481 million, while royalty revenue increased 50% to $307.7 million. Adjusted EBITDA reached $328.8 million and non-GAAP EPS was $2.28.
• 2026 guidance was raised: Halozyme now expects total revenue of $1.835 billion-$1.91 billion, royalty revenue of $1.22 billion-$1.245 billion, adjusted EBITDA of $1.225 billion-$1.28 billion, and non-GAAP EPS of $8.65-$9.00.
• ENHANZE product diversification accelerated: Royalties from newer launches—including OCREVUS ZUNOVO, Opdivo Qvantig, and RYBREVANT SC—increased approximately 80% sequentially, complementing continued growth from DARZALEX SC, VYVGART Hytrulo, and PHESGO.
• Strong partnership momentum expanded the long-term pipeline: Halozyme signed five collaboration and licensing agreements across the quarter and July, including deals with GSK, Incyte, Vertex, and Oruka, generating $35.5 million in upfront revenue and expanding ENHANZE into ADCs and nucleic-acid therapies.
• Litigation remains an important uncertainty: Halozyme is pursuing injunctions against Merck in roughly eight countries and plans to appeal four U.S. patent-review decisions, although management expressed strong confidence it will ultimately prevail.

Halozyme Therapeutics Stock Up 20.2%

NASDAQ HALO traded up $17.36 during trading hours on Friday, hitting $103.12. 7,632,978 shares of the company traded hands, compared to its average volume of 1,834,638. The business’s 50-day moving average is $75.74 and its 200-day moving average is $71.25. Halozyme Therapeutics has a twelve month low of $61.22 and a twelve month high of $103.30. The company has a debt-to-equity ratio of 8.81, a quick ratio of 2.33 and a current ratio of 2.76. The stock has a market capitalization of $12.23 billion, a price-to-earnings ratio of 37.09, a P/E/G ratio of 0.35 and a beta of 0.85.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on HALO shares. Citizens Jmp increased their price objective on shares of Halozyme Therapeutics from $92.00 to $93.00 and gave the stock a “market outperform” rating in a research report on Friday. Morgan Stanley cut their target price on Halozyme Therapeutics from $96.00 to $93.00 and set an “overweight” rating on the stock in a research note on Tuesday, May 12th. Leerink Partners raised shares of Halozyme Therapeutics from a “market perform” rating to an “outperform” rating and set a $110.00 price target for the company in a research note on Friday. HC Wainwright lifted their price objective on shares of Halozyme Therapeutics from $95.00 to $115.00 and gave the company a “buy” rating in a report on Friday. Finally, Weiss Ratings raised shares of Halozyme Therapeutics from a “buy (b-)” rating to a “buy (b)” rating in a research report on Friday, July 31st. Nine analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $91.20.

Halozyme Therapeutics News Roundup

Here are the key news stories impacting Halozyme Therapeutics this week:

• Positive Sentiment: Strong Q2 earnings beat: Halozyme reported adjusted earnings of $2.28 per share, versus the $1.79-$1.82 consensus range, while revenue rose 48% year over year to $481 million, well above the roughly $402 million estimate. Royalty revenue increased 50% to $308 million, highlighting continued momentum in the company’s ENHANZE platform. Halozyme Reports Record Second Quarter 2026 Results
• Positive Sentiment: Raised 2026 guidance: The company now expects revenue of $1.835-$1.910 billion, royalty revenue of $1.220-$1.245 billion, adjusted EBITDA of $1.225-$1.280 billion and non-GAAP EPS of $8.65-$9.00. The EPS outlook is above the prior consensus estimate of $8.02, signaling management’s confidence in sustained growth. Halozyme Q2 Earnings Beat Estimates
• Positive Sentiment: Business development exceeded expectations: Halozyme signed five new ENHANZE and Hypercon collaboration agreements year to date, already surpassing its full-year goal of three. These agreements could expand future royalty and licensing revenue.
• Positive Sentiment: Analyst support improved: Leerink Partners upgraded HALO to “outperform” with a $110 target, while HC Wainwright raised its target to $115 and maintained a “buy” rating.
• Neutral Sentiment: Citizens JMP raised its target to $93 and kept a “market outperform” rating; Wells Fargo lifted its target to $95 but maintained an “equal weight” rating. Both targets remain below the current trading level, indicating some analyst caution after the rally.
• Negative Sentiment: With HALO trading near its 52-week high, valuation and profit-taking risks may limit additional near-term gains despite the strong fundamental update.

Insider Buying and Selling at Halozyme Therapeutics

In other Halozyme Therapeutics news, Director Mahesh Krishnan sold 7,304 shares of the business’s stock in a transaction that occurred on Monday, June 29th. The stock was sold at an average price of $75.00, for a total transaction of $547,800.00. Following the transaction, the director owned 14,462 shares of the company’s stock, valued at $1,084,650. The trade was a 33.56% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Bernadette Connaughton sold 1,625 shares of the company’s stock in a transaction that occurred on Wednesday, July 1st. The stock was sold at an average price of $76.71, for a total value of $124,653.75. Following the sale, the director owned 42,044 shares in the company, valued at approximately $3,225,195.24. This represents a 3.72% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 72,477 shares of company stock worth $5,102,643 over the last ninety days. 2.50% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Larson Financial Group LLC lifted its stake in Halozyme Therapeutics by 3,118.2% in the 3rd quarter. Larson Financial Group LLC now owns 354 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 343 shares during the last quarter. Wexford Capital LP bought a new position in Halozyme Therapeutics in the 3rd quarter valued at about $70,000. Employees Retirement System of Texas lifted its position in Halozyme Therapeutics by 64.6% during the third quarter. Employees Retirement System of Texas now owns 1,088 shares of the biopharmaceutical company’s stock worth $80,000 after acquiring an additional 427 shares during the last quarter. UMB Bank n.a. lifted its position in Halozyme Therapeutics by 18.2% during the fourth quarter. UMB Bank n.a. now owns 1,296 shares of the biopharmaceutical company’s stock worth $87,000 after acquiring an additional 200 shares during the last quarter. Finally, Smartleaf Asset Management LLC boosted its holdings in shares of Halozyme Therapeutics by 21.9% during the fourth quarter. Smartleaf Asset Management LLC now owns 1,399 shares of the biopharmaceutical company’s stock worth $95,000 after acquiring an additional 251 shares during the period. Institutional investors own 97.79% of the company’s stock.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.